ERBB2 and neoplasm: We focused on ovarian cancer cell lines with overexpression of Human Epidermal growth factor Receptor 2 (HER2), which is a marker of tumor aggressiveness and low patient survival rate due to the developed resistance to both classical chemotherapeutics [31] and targeted drugs [32,33].